More news – Page 10
-
NewsModerna-Merck & Co cancer vaccine with Keytruda shows late-stage promise
New phase IIb data highlights the combination’s potential to offer improved efficiency to high-risk melanoma patients.
-
NewsGenentech doubles investment in North Carolina manufacturing facility
The East Coast expansion is part of the biopharma firm’s $50 billion investment in its US manufacturing and R&D capabilities.
-
NewsEurope marks key milestone in adopting Critical Medicines Act
EU Parliament agrees clear priorities for future negotiations on the act, including investing in pharma manufacturing capacity.
-
NewsGSK acquires food allergy firm Rapt Therapeutics for $2.2bn
Will gain access to ozureprubart, a potential best-in-class antibody for food allergies, and expand its respiratory, immunology and inflammation pipeline.
-
News
Biomanufacturing framework could boost microbial production efficiency
Research findings support the design of robust microbial processes for pharmaceutical products.
-
NewsEU concludes major free trade agreement with Mercosur countries
European pharma industry acknowledges the progress made, particularly with partial tariff reductions, but said further provisions could have been achieved.
-
NewsKincell Bio promotes Bruce Thompson to President and Chief Technology Officer
The cell therapy-focused CDMO has also elevated Melodie Bryce to Chief Quality Officer and Matt Haines to Chief Operations Officer.
-
News
Yeast research could advance sustainable pharmaceutical bioproduction
Novel approach holds potential to reduce the industry’s dependence on coconut and palm oil extraction for bioproduction of short- and medium-chain fatty acids.
-
NewsTeva’s migraine biologic Ajovy marks phase III progress for paediatric patients
The monoclonal antibody could provide a new preventative treatment option for episodic migraines, new late-stage data suggests.
-
NewsPolymer capsule drug delivery innovation demonstrates sustainability promise
Synthesis of the naturally-derived capsules provide a sustainable alternative to traditional, microplastic-contributing drug delivery options.
-
News
Automation joins AI and cybersecurity as digital priorities for Indian pharma
But the sector’s digital transformation ambitions within their quality functions have only been partially realised.
-
NewsEMA and FDA issue joint AI guidance for medicine development
The regulators’ 10 principles aim to support pharma companies with evidence generation and monitoring for new medicines.
-
NewsAI framework could enhance continuous manufacturing, say FDA researchers
Digital twin model offers potential for advanced control during continuous pharmaceutical manufacturing processes.
-
News
AbbVie licenses novel bispecific antibody from RemeGen for $5bn
New deal strengthens AbbVie's oncology portfolio, adding a new class of cancer therapeutics to its inventory.
-
NewsEuropean Pharmacopoeia publishes new data quality framework
New general chapter on quality of data 5.38 supports stakeholders with digitalisation during pharmaceutical quality decision-making.
-
NewsSentynl secures US-first approval for rare Menkes disease
The US biopharma company can now offer a new treatment option for eligible paediatric patients with the genetic disease.
-
NewsSanofi wins EU approval for its type 1 diabetes biologic Teizeild
The European Commission’s decision will make the product the first disease-modifying treatment to be available for the condition in Europe.
-
NewsNovartis to site its fourth US radioligand manufacturing facility in Florida
The new Winter Park plant advances the pharma company’s $23 billion commitment to enhance its US radioligand medicine manufacturing capabilities.
-
NewsEndotoxins research supports recombinant reagent use for pharma QC
Replacing LAL reagents with animal-free alternatives addresses industry commitments to improve QC practices’ ethics and sustainability.
-
NewsAstraZeneca hires Rick Suarez to lead its biopharma efforts in the US
His appointment comes as the pharma company AstraZeneca seeks to hit $80 billion revenue target by 2030.